Article
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Cancer prevention research (Philadelphia, Pa.) - 1 Feb 2012
Arun Banu, Valero Vicente, Liu Diane, Brewster Abenaa, Green Marjorie, Gutierrez-Barrera Angelica, Akar Ugur, Rivera Edgardo, Esteva Francisco J, Buzdar Aman U, Hortobagyi Gabriel N, Sneige Nour
Abstract excerpt
The selective estrogen receptor modulators (SERM), Tamoxifen and raloxifen reduce risk breast cancer. Patient acceptance of SERMs for breast cancer prevention is low due to toxicities. New agents with a better toxicity profile are needed. Aromatase inhibitors (AI) reduce the risk of contralateral breast cancer and risk of new breast cancer in high risk women. However, the mechanism by which AIs reduce breast risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.